| Literature DB >> 32563921 |
Chanon Ngamsombat1, Qiyuan Tian2, Qiuyun Fan2, Andrew Russo3, Natalya Machado3, Maya Polackal2, Ilena C George3, Thomas Witzel2, Eric C Klawiter3, Susie Y Huang4.
Abstract
INTRODUCTION: White matter damage in the visual pathway is common in multiple sclerosis (MS) and is associated with retinal thinning, although the underlying mechanism of association remains unclear. The goal of this work was to evaluate the presence and extent of white matter tract integrity (WMTI) alterations in the optic radiation (OR) in people with MS and to investigate the association between WMTI metrics and retinal thinning in the eyes of MS patients without a history of optic neuritis (ON) as measured by optical coherence tomography (OCT). We hypothesized that WMTI metrics would reflect axonal damage that occurs in the OR in MS, and that axonal alterations revealed by WMTI would be associated with retinal thinning.Entities:
Keywords: Diffusion tractography; Multiple sclerosis; Optic radiation; Optical coherence tomography; Retinal thinning; White matter tract integrity
Mesh:
Year: 2020 PMID: 32563921 PMCID: PMC7305426 DOI: 10.1016/j.nicl.2020.102293
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Fig. 1Diffusion tractography results of the optic radiation (OR) in a representative MS patient. (a) Lateral geniculate nucleus (LGN) region-of-interest (ROI). (b) Subcortical white matter of the primary visual cortex (V1) ROI. (c) Volume-rendered thresholded probabilistic tractography results for the OR (yellow), LGN ROI (red) and V1 ROI (green). (d) Volume-rendered thresholded probabilistic tractography results for the OR (yellow) with segmented MS lesions (purple). The white arrow highlights the MS lesion in the OR while the blue arrow highlights the normal appearing white matter of the OR. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Demographic and clinical information for healthy control subjects and multiple sclerosis patients.
| HC (n = 29) | MS (n = 29) | MS_NON (n = 18) | MS_ON (n = 11) | p-value (MS_NON vs MS_ON) | |
|---|---|---|---|---|---|
| Age (Y), mean ± SD [range] | 41.72 | 42.83 | 45.94 | 37.73 | 0.07 |
| Sex (M/F) | 11/18 | 7/22 | 6/12 | 1/10 | 0.30 |
| Disease duration (Y), mean ± SD [range] | NA | 8.66 | 9.1 | 7.91 | 0.65 |
| MS subtype (RRMS/SPMS) | NA | 24/5 | 16/2 | 8/3 | 0.54 |
| Disease-modifying therapy, n (%), RRMS/SPMS | 27 (93.1%), 24/3 | 17 (94.4%), 16/1 | 10 (90.9%), 8/2 | 0.69 | |
| Dimethyl fumarate | 8 (27.6%), 8/0 | 4 (22.2%), 4/0 | 4 (36.4%), 4/0 | ||
| Glatiramer acetate | 7 (24.1%), 7/0 | 5 (27.8%), 5/0 | 2 (18.2%), 2/0 | ||
| β-interferons | 1 (3.4%), 1/0 | 0 | 1 (9.1%), 1/0 | ||
| Fingolimod | 4 (13.8%), 3/1 | 4 (22.2%), 3/1 | 0 | ||
| Natalizumab | 2 (6.9%), 2/0 | 1 (5.6%), 1/0 | 1 (9.1%), 1/0 | ||
| Rituximab | 2 (6.9%), 0/2 | 0 | 2 (18.2%), 0/2 | ||
| Ocrelizumab | 3 (10.3%), 3/0 | 3 (16.7%), 3/0 | 0 | ||
| None | 2 (6.9%), 0/2 | 1 (5.6%), 0/1 | 1 (9.1%), 0/1 | ||
| EDSS score, mean ± SD, median [range] | NA | 2.83 | 2.75 | 2.95 | 0.51 |
| Mean RNFL, mean ± SD [range] | NA | 91.85 | 91.66 | 92.17 | 0.93 |
| Mean GCL + IPL, mean ± SD [range] | NA | 78.91 | 80.36 | 76.55 | 0.39 |
| Mean letter acuity score at 100% contrast, mean ± SD [range] | NA | 51.3 | 53.28 | 48.45 | 0.21 |
| Mean letter acuity score at 2.5% contrast, mean ± SD [range] | NA | 26.3 | 28.84 | 26.91 | 0.82 |
| Mean letter acuity score at 1.25% contrast, mean ± SD [range] | NA | 7.3 | 3.53 | 12.7 | 0.02 |
Note. – EDSS = Expanded Disability Status Scale, NA = not applicable, RNFL = retinal nerve fiber layer thickness, GCL + IPL = ganglion cell layer thickness (GCL) combined with the inner plexiform layer (IPL). RNFL and GCL + IPL are reported in microns.
Student’s t-test.
Chi-Square Test.
Wilcoxon rank-sum test.
Comparison of the OR diffusion metrics between HCs and MS patients.
| Diffusion MR metrics | HC | MS | p-value | ||
|---|---|---|---|---|---|
| NAWM | Lesion | HC vs NAWM | NAWM vs Lesion | ||
| FA | 0.52 (0.02) | 0.49 (0.041) | 0.36 (0.08) | <0.001 | <0.001 |
| MD (×10−3) | 0.91 (0.04) | 1.01 (0.19) | 1.26 (0.19) | 0.014 | <0.001 |
| AD (×10−3) | 1.50 (0.06) | 1.59 (0.29) | 1.76 (0.24) | 0.1 | 0.03 |
| RD (×10−3) | 0.61 (0.04) | 0.71 (0.16) | 1.00 (0.19) | 0.003 | <0.001 |
| AWF | 0.39 (0.02) | 0.36 (0.03) | 0.27 (0.03) | <0.001 | <0.001 |
| Da | 1.05 (0.06) | 1.04 (0.06) | 0.99 (0.17) | 0.7 | 0.13 |
| De, perp | 1.03 (0.05) | 1.09 (0.14) | 1.4 (0.28) | 0.02 | <0.001 |
| De, || | 2.36 (0.09) | 2.36 (0.19) | 2.44 (0.38) | 0.9 | 0.4 |
| Tort | 2.48 (0.17) | 2.33 (0.21) | 1.77 (0.29) | 0.004 | <0.001 |
Note. – Diffusion metric differences between MS from HCs were assessed using Student’s t tests. Mean values are reported with standard deviations shown in parentheses.
Denotes significance following correction for multiple comparisons (FDR threshold of 0.05). Raw p-values are reported in the table.
Correlation between diffusion metrics in OR NAWM and OCT data in patients with no previous history of optic neuritis (MS_NON, N = 18).
| Diffusion metrics | Average RNFL | Nasal RNFL | Temporal RNFL | GCL + IPL |
|---|---|---|---|---|
| FA | 0.55 (0.03) | 0.45 (0.09) | 0.37 (0.18) | 0.39 (0.15) |
| MD | −0.48 (0.07) | −0.2 (0.46) | −0.57 (0.03) | −0.39 (0.15) |
| AD | −0.27 (0.34) | 0.03 (0.9) | −0.51 (0.05) | −0.27 (0.33) |
| RD | −0.54 (0.037) | −0.3 (0.26) | −0.55 (0.035) | −0.4 (0.1) |
| AWF | 0.68 (0.005)* | 0.52 (0.046) | 0.47 (0.08) | 0.52 (0.048) |
| Da | 0.5 (0.057) | 0.47 (0.07) | 0.19 (0.5) | 0.24 (0.39) |
| De, perp | −0.2 (0.47) | −0.04 (0.9) | −0.36 (0.2) | −0.03 (0.9) |
| De, || | 0.39 (0.15) | 0.54 (0.038) | −0.06 (0.8) | 0.3 (0.23) |
| Tort | 0.42 (0.12) | 0.38 (0.16) | 0.29 (0.29) | 0.23 (0.4) |
Note. – Correlation analysis using weighted Pearson partial correlation coefficients controlled for age, sex and disease duration. Raw p-values are shown in parentheses. *denotes significant correlations following correction for multiple comparisons (FDR threshold of 0.05).
Correlation analysis between diffusion metrics in OR NAWM and visual acuity scores at 100%, 2.5%, and 1.25% contrast for MS patients.
| Diffusion metrics | VA at 100% contrast | VA at 2.5% contrast | VA at 1.25% contrast |
|---|---|---|---|
| FA | −0.2 (0.4) | −0.1 (0.6) | −0.14 (0.56) |
| MD | −0.04 (0.9) | 0.197 (0.42) | 0.53 (0.018) |
| AD | −0.08 (0.7) | 0.199 (0.41) | 0.55 (0.01) |
| RD | 0.002 (0.99) | 0.191 (0.43) | 0.5 (0.03) |
| AWF | −0.1 (0.6) | −0.019 (0.9) | −0.24 (0.33) |
| Da | −0.2 (0.4) | −0.076 (0.76) | 0.32 (0.18) |
| De, perp | 0.13 (0.6) | 0.21 (0.38) | 0.33 (0.16) |
| De, || | 0.03 (0.9) | 0.29 (0.23) | 0.54 (0.02) |
| Tort | −0.1 (0.6) | −0.082 (0.74) | 0.02 (0.93) |
Note. – Correlation analysis using Pearson partial correlation coefficients adjusting for age, sex and disease duration (p-values are shown in parentheses). Only cases with RNFL thickness >80 μm (N = 22) were included in the analysis.
*Denotes significance following correction for multiple comparisons (FDR threshold of 0.05). Raw p-values are reported in the table.